M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 3.93 EUR -5.53%
Market Cap: 63.4m EUR

EV/EBIT
Enterprise Value to EBIT

-2
Current
-3.4
Median
6.5
Industry
Higher than median
Lower than industry value
Created with Highcharts 11.4.8Jan '22May '22Sept '22Jan '23May '23Sept '23Jan '24May '24Sept '24Jan '25May '25Sept '250
Nov-2025
Negative
EV/EBIT

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-2
=
Enterprise Value
60.2m EUR
/
EBIT
-30.4m EUR
EBIT Growth EV/EBIT to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBIT: 25.4
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 709.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.6
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
12%
1.6
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -307 N/A N/A
NL
argenx SE
XBRU:ARGX
64.8
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2
2-Years Forward
EV/EBIT
-1.7
3-Years Forward
EV/EBIT
-2